Stockscreener 앱 받기
108.96
1.86%
2.22
Glaukos Corporation 주식(GKOS)의 최신 뉴스
Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Stifel reiterates Buy rating on Glaukos stock with $160 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Glaukos stock with $160 price target - Investing.com Australia
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
What is Glaukos Corporation’s market position2025 Major Catalysts & Weekly Momentum Picks - mfd.ru
Glaukos (GKOS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Glaukos Corporation $GKOS Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
C WorldWide Group Holding A S Acquires 45,000 Shares of Glaukos Corporation $GKOS - MarketBeat
How FDA Approval of Repeat iDose TR Use Will Impact Glaukos (GKOS) Investors - simplywall.st
Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC - MarketBeat
Liquidity Mapping Around (GKOS) Price Events - Stock Traders Daily
Director Sells GKOS 15,000 Shares for $1.9 Million - AOL.com
11,479 Shares in Glaukos Corporation $GKOS Bought by Y Intercept Hong Kong Ltd - MarketBeat
Assessing Glaukos (GKOS) Valuation After FDA Approval For Repeat iDose TR Use - simplywall.st
Glaukos Gains FDA Green Light For Repeat iDose TR Use - Yahoo Finance
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential - Yahoo Finance
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR - Yahoo Finance UK
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant - Yahoo Finance
Market Review: Will Glaukos Corporation outperform its industry peersJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Glaukos Achieves Regulatory and Commercial Milestones - AD HOC NEWS
Universal Beteiligungs und Servicegesellschaft mbH Sells 28,088 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos rises as FDA greenlights labeling update for iDose TR - MSN
Is Neonode Inc forming bullish engulfing patternsQuarterly Portfolio Summary & High Return Stock Watch Alerts - baoquankhu1.vn
Wells sees potential upside after Glaukos’ iDose repeat dosing label approved - Yahoo Finance
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Finviz
FDA approves Glaukos' iDose TR for repeat treatment labeling - Eyes On Eyecare
AustralianSuper Pty Ltd Increases Stock Position in Glaukos Corporation $GKOS - MarketBeat
Is Glaukos Corporation gaining market shareDip Buying & Free High Return Stock Watch Alerts - Mfd.ru
Glaukos Corporation (NYSE:GKOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Glaukos Receives FDA Approval of NDA Supplement for Re-Administration of iDose TR - VisionMonday.com
FDA approves repeat treatment protocol for Glaukos’ iDose TR By Investing.com - Investing.com South Africa
Glaukos (NYSE:GKOS) Trading 6% Higher Following Analyst Upgrade - MarketBeat
Glaukos (NYSE:GKOS) Price Target Raised to $131.00 - MarketBeat
GKOS: BTIG Raises Price Target to $131 Amid Confidence in Glaukos | GKOS Stock News - GuruFocus
Glaukos stock rises on FDA approval for iDose TR re-administration - Investing.com
Glaukos stock rises on FDA approval for iDose TR re-administration By Investing.com - Investing.com South Africa
Glaukos (GKOS) Gains FDA Nod for iDose TR Re-administration Prot - GuruFocus
Glaukos (GKOS) Achieves FDA Approval for iDose Repeat Dosing Lab - GuruFocus
Glaukos wins FDA nod for iDose TR labeling update (GKOS:NYSE) - Seeking Alpha
Glaukos stock price target raised to $131 from $123 at BTIG on iDose approval By Investing.com - Investing.com Nigeria
Glaukos stock price target raised to $131 from $123 at BTIG on iDose approval - Investing.com Australia
FDA Approves Glaukos (GKOS) Repeat Administration Protocol for i - GuruFocus
Glaukos announces US FDA approval of NDA supplement allowing for re-administration of Idose® Tr - marketscreener.com
FDA approves repeat treatment protocol for Glaukos’ iDose TR - Investing.com
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire
Glaukos Corp (GKOS) Shares Gap Down to $120.3 on Jan 27 - GuruFocus
1.74%
1.02%
자본화:
|
볼륨(24시간):